跳至主要内容
临床试验/NCT01437215
NCT01437215已完成不适用

Prospective, Multicenter, Single Arm Feasibility and Initial Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms

Endologix2 个研究点 分布在 2 个国家目标入组 15 人开始时间: 2010年11月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
15
试验地点
2
主要终点
Safety - Number of Major Adverse Events (MAEs)

研究概览

简要总结

The purpose of this study is to determine whether the Endologix fenestrated stent graft system is safe and feasible in the endovascular repair of juxtarenal or pararenal aortic aneurysm.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Informed consent understood and signed and pt agrees to all follow-up visits;
  • Abdominal aortic aneurysm with diameter ≥5cm or ≥4cm which has increased by 0.5cm or more in the past six months
  • Adequate iliac/femoral access compatible with the required delivery systems
  • Non-aneurysmal infrarenal aortic neck <15mm in length
  • Most caudal renal artery to aortoiliac bifurcation length at least 70mm
  • Proximal non-aneurysmal aortic neck below the SMA with: diameter 18 to 34 mm; length at least 15 mm; angle (clock face) <60° to the aneurysm sac;
  • Angle <60° (clock face) between the SMA and celiac artery
  • Renal arteries both distal to the SMA by 0-35mm, within 30mm of each other axially, with 4 to 8mm lumen diameter, and with clockface angle of 90° to 210° to each other
  • Iliac anatomy suitable for commercial bifurcated stent graft;
  • Minimum 3cm overlap achievable between fenestrated and bifurcated stent grafts

排除标准

  • Life expectancy <1 year as judged by the investigator;
  • Psychiatric or other condition that may interfere with the study;
  • Participating in the enrollment or 30-day follow-up phase of another clinical study;
  • Known allergy to any device component;
  • Coagulopathy or uncontrolled bleeding disorder;
  • Contraindication to contrast media or anticoagulants;
  • Ruptured, leaking, dissecting, or mycotic aneurysm;
  • Serum creatinine (S-Cr) level >2.0 mg/dL;
  • Traumatic vascular injury;
  • Active systemic or localized groin infection;
  • Connective tissue disease (e.g., Marfan's Syndrome);
  • Recent (within prior three months) cerebrovascular accident or myocardial infarction;
  • Prior renal transplant;
  • Length of either renal artery to be stented <13mm;
  • Significant occlusive disease or calcification of either renal artery;
  • An essential accessory renal artery;
  • Indispensable inferior mesenteric artery;
  • Untreated aneurysmal disease of the descending thoracic aorta;
  • Clinically significant mural thrombus circumferentially in the suprarenal segment;
  • Prior iliac artery stent implanted that may interfere with delivery system introduction;
  • Unsuitable vascular anatomy
  • Pregnancy (female patient of childbearing potential only)

结局指标

主要结局

Safety - Number of Major Adverse Events (MAEs)

时间窗: 30 Days

Major Adverse Events = all cause death; bowel ischemia; myocardial infarction; paraplegia; renal failure; respiratory complications of stroke; blood loss \>1000cc

Feasibility- Number of subjects with procedural success (stent graft patency) and absence of type I/III endoleaks or migration

时间窗: 30 Days

Procedural Success with aortic/fenestrated and renal stent graft patency and absence of Type I/III endoleak or migration

次要结局

  • Adverse Events(Procedurally to 5 Years)
  • Safety - Number of Major Adverse Events (MAEs)(>30 Days to 5 Years)
  • Distal Blood Flow(Discharge to 5 Years)
  • Device Performance(30 Days to 5 Years)
  • Renal Dysfunction(Discharge to 5 Years)

研究者

发起方
Endologix
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验